NKF Innovation Fund invests in 34 Lives to accelerate development of proprietary process
Click Here to Manage Email Alerts
The National Kidney Foundation Innovation Fund announced an investment in 34 Lives, a startup company that is developing a proprietary process to rehabilitate donated kidneys, according to a press release.
“Every day in the U.S., approximately 34 lives are lost waiting for an organ transplant,” Chris Jaynes, founder and CEO of 34 Lives, said in the release. “There are 120,000 American[s] on organ transplant waiting lists and 84% of those are waiting for a kidney. They wait and they wait – on average for 6 years. That’s why we named our company 34 Lives, it’s our name and our mission.”
The company aims to bring kidneys back up to normal body temperature so that the organs can be ready for transplantation. According to the release, 34 Lives intends to provide an additional 20 hours of viability for delivery and transplantation to at least 80% of cases.
By investing, the NKF Innovation Fund plans to accelerate the development of 34 Lives.
“When we launched the NKF Innovation Fund in April, it was with the idea that we needed to disrupt the kidney care landscape,” Kevin Longino, CEO of NKF and a kidney transplant patient, said in the release. “34 Lives processes are precisely what we had in mind. The potential to save lives here is just incredible, and NKF is honored to help fund its development.”
Read more about
Click Here to Manage Email Alerts